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Livigni and coworkers [1] reported on the safety and efficacy
of a venovenous carbon dioxide removal (VVCO2R) circuit in
a short-term study (to 12 hours) conducted in healthy sheep.
During extracorporeal carbon dioxide removal, carbon dioxide
is transferred across a gas exchanger whereas oxygen
diffuses across the native lungs.
In 1969 Kolobow and coworkers [2] described use of
VVCO2R in healthy sheep for 1 week, and they later demon-
strated improved survival in injured sheep [3]. Clinical trials,
however, failed to show improved outcomes [4].
Arteriovenous carbon dioxide removal (AVCO2R), as a simple
arteriovenous shunt, eliminates several circuit components.
AVCO2R removes near total carbon dioxide production with
only 1 l/min (approximately 15% of cardiac output) blood flow
and appears to be effective in acute respiratory distress
disorder (ARDS), as shown in prospective randomized large
animal and preliminary clinical trials.
Our sheep model of severe ARDS is based on a third degree
burn to 40% of the total body surface area and 48-breath
smoke inhalation injury [5]. Because the median duration of
AVCO2R treatment for ARDS is 4.8 days, our model allows
comparison of ventilatory techniques over 5 days to evaluate
pathophysiology and outcomes [6].
Based on the experience with carbon dioxide removal, two
major concerns arise. First, the circuit blood flow employed by
Livigni and coworkers is only 5% of the cardiac output, which
was inadequate to achieve normalization of arterial carbon
dioxide pressure (PaCO2). Use of larger cannulae (12 to 15 Fr)
would allow flows up to 1 l/min. Second, studies of such short
duration in healthy animals have limited clinical relevance [7].
We wonder whether the methods employed by Livigni and
coworkers would have an impact on survival in 5-day large
animal studies of lung injury or in clinical application.
Letter
Carbon dioxide removal device: how long is long enough?
Manuel E Cevallos and Joseph B Zwischenberger
Cardiothoracic Surgery Department. The University of Texas Medical Branch, 301 University Boulevard, Galveston, Texas 77555-0828, USA
Correspondence: Manuel Cevallos, mecevall@utmb.edu
Published: 29 January 2007 Critical Care 2007, 11:405 (doi:10.1186/cc5130)
This article is online at http://ccforum.com/content/11/1/405
© 2007 BioMed Central Ltd
See related research by Livigni et al., http://ccforum.com/content/10/6/R151
ARDS = acute respiratory distress disorder; PaCO2 = arterial carbon dioxide pressure; VVCO2R = venovenous carbon dioxide removal.
Authors’ response
Sergio Livigni, Marco Vergano and Guido Bertolini
In response to the concerns raised by Cevallos and
Zwischenberger, we should like to stress the following points.
First, since the 1970s many things have changed both in
research methodology and in clinical practice. From a
research perspective, clear evidence of the efficacy/futility of
techniques (in this case arteriovenous and venovenous) now
requires much greater effort in terms of patient numbers (in
some cases the number of patients required to achieve
statistical significance is greater than the number actually
available) and study design. From a clinical perspective
ventilatory strategies are now rather different, with much
greater emphasis on protective approaches and avoiding
high tidal volume and high pressure.
Second, our target was not to normalize carbon dioxide.
However, we believe that 20% carbon dioxide removal using
low flows is an interesting result.
Third, in accordance with the prevailing desire to employ
gentle ventilatory strategies, we are simply looking for an easy
and feasible technique to allow routine ventilation in ARDS
patients to confer greater protection.
Fourth, we favor a venovenous technique because it is more
easily managed in intensive care units with basic experience
in continuous renal replacement techniques and can easily be
integrated into multiple organ support therapy.Page 2 of 2
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Finally, it is clear that higher flow rates permit a more
consistent carbon dioxide removal; for low flow rates
(<1 l/min) we believe that the risk/benefit ratio of
arteriovenous access would be too high. If the patient’s
condition mandates higher rates, then we would prefer
extracorporeal membrane oxygenation or a method that
would improve not only carbon dioxide control but also
oxygenation.
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